{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:09:52Z","timestamp":1761620992241},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.parkreldis.2008.04.036","type":"journal-article","created":{"date-parts":[[2008,6,17]],"date-time":"2008-06-17T09:13:05Z","timestamp":1213693985000},"page":"138-143","source":"Crossref","is-referenced-by-count":30,"title":["Sympathetic modulation by levodopa reduces vascular risk factors in\u00a0Parkinson disease"],"prefix":"10.1016","volume":"15","author":[{"given":"Giulio","family":"Scigliano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Ronchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floriano","family":"Girotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Musicco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2008.04.036_bib1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2165\/00003495-197816050-00003","article-title":"Catecholamines: role in health and disease","volume":"16","author":"Laverty","year":"1978","journal-title":"Drugs"},{"issue":"S 3","key":"10.1016\/j.parkreldis.2008.04.036_bib2","first-page":"11","article-title":"The sympathetic nervous system in the pathogenesis of hypertension","volume":"17","author":"Rahn","year":"1999","journal-title":"J Hypertens"},{"issue":"5","key":"10.1016\/j.parkreldis.2008.04.036_bib3","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/01.HYP.21.5.618","article-title":"Reflex sympathetic activation induces acute insulin resistance in the human forearm","volume":"21","author":"Jamerson","year":"1993","journal-title":"Hypertension"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib4","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.284.6323.1145","article-title":"Adrenergic mechanism in control of plasma lipid concentrations","volume":"284","author":"Day","year":"1982","journal-title":"BMJ"},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2008.04.036_bib5","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1291\/hypres.18.SupplementI_S79","article-title":"Role of endogenous dopamine in modulating sympathetic-adrenal activity in humans","volume":"18","author":"Mannelli","year":"1995","journal-title":"Hypertens Res"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib6","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/000331979104200902","article-title":"Effect of L-dopa in young patients with hypertension","volume":"42","author":"Saito","year":"1991","journal-title":"Angiology"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jnnp.58.3.293","article-title":"Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?","volume":"58","author":"Ben-Shlomo","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib8","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/01.STR.21.10.1395","article-title":"Stroke and its modification in Parkinson's disease","volume":"21","author":"Struck","year":"1990","journal-title":"Stroke"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.parkreldis.2008.04.036_bib10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2165\/00003495-197102040-00002","article-title":"Levodopa. a review of its pharmacological properties and therapeutic uses with particular reference to parkinsonism","volume":"2","author":"Brogden","year":"1971","journal-title":"Drugs"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/cpt1970115740","article-title":"Effect of L-dopa alone and in combination with extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes","volume":"11","author":"Watanabe","year":"1970","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1365-2125.1997.00610.x","article-title":"Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics","volume":"44","author":"Dingemanse","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1161\/01.RES.27.4.561","article-title":"Attenuation of postganglionic sympathetic nerve activity by L-dopa","volume":"27","author":"Whitsett","year":"1970","journal-title":"Circ Res"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib14","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1038\/sj.jhh.1000987","article-title":"Dopamine: a role in the pathogenesis and treatment of hypertension","volume":"14","author":"Murphy","year":"2000","journal-title":"J Hum Hypertens"},{"issue":"Suppl 2","key":"10.1016\/j.parkreldis.2008.04.036_bib15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2337\/db06-S013","article-title":"Neuropeptides and the regulation of islet function","volume":"55","author":"Ahren","year":"2006","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.parkreldis.2008.04.036_bib16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/BF00296990","article-title":"Insulin resistance in type 1 (insulin-dependent) diabetes following hypoglycaemia\u2014evidence for the importance of beta-adrenergic stimulation","volume":"30","author":"Attvall","year":"1987","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.parkreldis.2008.04.036_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s001250051341","article-title":"New insights into sympathetic regulation of glucose and fat metabolism","volume":"43","author":"Nonogaki","year":"2000","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.parkreldis.2008.04.036_bib18","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2337\/diacare.20.11.1697","article-title":"Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women","volume":"20","author":"Kamath","year":"1997","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.parkreldis.2008.04.036_bib19","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2337\/diacare.23.8.1154","article-title":"Bromocriptine: a novel approach to the treatment of type 2 diabetes","volume":"23","author":"Pijl","year":"2000","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.parkreldis.2008.04.036_bib20","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1517\/13543784.8.10.1683","article-title":"Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes","volume":"8","author":"Cincotta","year":"1999","journal-title":"Expert Opin Invest Drugs"},{"issue":"1","key":"10.1016\/j.parkreldis.2008.04.036_bib21","first-page":"1","article-title":"Renal nerves in the pathogenesis of hypertension in experimental animals and humans","volume":"245","author":"Katholi","year":"1983","journal-title":"Am J Physiol"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1126\/science.165.3890.291","article-title":"Renin-aldosterone system in Parkinson's disease","volume":"165","author":"Barbeau","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1042\/cs0610187","article-title":"Inhibition of the renin-angiotensin-aldosterone system by L-dopa with and without inhibition of extracerebral dopa decarboxylase in man","volume":"61","author":"Barbieri","year":"1981","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1161\/01.CIR.72.2.245","article-title":"Dopamine receptors: applications in clinical cardiology","volume":"72","author":"Goldberg","year":"1985","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.parkreldis.2008.04.036_bib25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1210\/jcem-44-1-196","article-title":"The effect of dopamine infusion on insulin and glucagon secretion in man","volume":"44","author":"Leblanc","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib26","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/01.STR.0000217384.03237.9c","article-title":"Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study","volume":"37","author":"Scigliano","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib27","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.277.22.1775","article-title":"Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project","volume":"277","author":"Graham","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.parkreldis.2008.04.036_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneur.60.1.59","article-title":"Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease","volume":"60","author":"Rogers","year":"2003","journal-title":"Arch Neurol"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802008001478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802008001478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T20:52:51Z","timestamp":1545943971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802008001478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S1353802008001478"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2008.04.036","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}